| Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) (NCT00988728) | Merck Sharp & Dohme LLC | 2011-02-01 |
| CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness (NCT01149551) | US Department of Veterans Affairs | 2011-02-01 |
| Relapse Prevention Study in Patients With Schizophrenia (NCT01291511) | Vanda Pharmaceuticals | 2011-02-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia (NCT01234779) | Hoffmann-La Roche | 2011-02-01 |
| Illness Management and Recovery (IMR) in Danish Community Mental Health Centres (NCT01361698) | Amager Hospital | 2011-02-01 |
| An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia (NCT01634542) | Hoffmann-La Roche | 2011-02-01 |
| Treating Refractory Schizophrenia With rTMS (NCT02242578) | Seton Healthcare Family | 2011-01-24 |
| Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders (NCT01831986) | Sha'ar Menashe Mental Health Center | 2011-01-01 |
| A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307) (NCT01235520) | Hoffmann-La Roche | 2011-01-01 |
| Treatment Development Targeting Severe and Persistent Negative Symptoms (NCT01550666) | The University of Texas Health Science Center at San Antonio | 2011-01-01 |
| Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression (NCT02661789) | Gitte Moos Knudsen | 2011-01-01 |
| Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia (NCT01295411) | Assistance Publique Hopitaux De Marseille | 2011-01-01 |
| Enhancing Synaptic Plasticity and Cognition in Schizophrenia (NCT01776112) | University Medical Center Goettingen | 2011-01-01 |
| Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia (NCT01315587) | University of Tehran | 2011-01-01 |
| Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects (NCT01289080) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-01-01 |
| Cognitive Behavioral Therapy for Patients With an Early Psychosis (NCT01511406) | Oslo University Hospital | 2011-01-01 |
| Brain Circuits in Schizophrenia and Smoking (NCT01425684) | University of Maryland, Baltimore | 2010-12-20 |
| A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) (NCT01192867) | Hoffmann-La Roche | 2010-12-11 |
| Acute Psychological Effects of High Intensity Exercise With Schizophrenia (NCT01310998) | Norwegian University of Science and Technology | 2010-12-01 |
| Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels (NCT02652832) | Hôpital le Vinatier | 2010-12-01 |
| Relative Effectiveness of Schizophrenia Therapy Study (NCT01245348) | Medco Health Solutions, Inc. | 2010-12-01 |
| A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects (NCT01299454) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2010-12-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306) (NCT01235585) | Hoffmann-La Roche | 2010-12-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305) (NCT01235559) | Hoffmann-La Roche | 2010-12-01 |
| A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309) (NCT01192906) | Hoffmann-La Roche | 2010-12-01 |
| Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States (NCT01425671) | University of Maryland, Baltimore | 2010-11-30 |
| Multimodal MRI-guided rTMS to Treat Refractory Hallucinations (NCT01373866) | University Hospital, Lille | 2010-11-15 |
| A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder (NCT01116830) | Hoffmann-La Roche | 2010-11-01 |
| A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NCT01192880) | Hoffmann-La Roche | 2010-11-01 |
| Paliperidone Palmitate Flexible Dosing in Schizophrenia (NCT01281527) | Janssen-Cilag International NV | 2010-11-01 |
| An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (NCT01309373) | Janssen-Cilag, S.A. | 2010-11-01 |
| Neurophysiological Targets for Cognitive Training in Schizophrenia (NCT00923078) | VA Office of Research and Development | 2010-11-01 |
| Evaluation of Mirtazapine and Folic Acid for Schizophrenia: (NCT01263080) | Capital Medical University | 2010-11-01 |
| Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia (NCT01213836) | AstraZeneca | 2010-11-01 |
| FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain (NCT01376492) | Janssen-Cilag, S.A. | 2010-11-01 |
| The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy (NCT01215383) | Ziv Hospital | 2010-11-01 |
| An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia (NCT02640911) | Shanghai Mental Health Center | 2010-11-01 |
| Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) (NCT01250847) | Severance Hospital | 2010-11-01 |
| Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics (NCT01246128) | National Institute on Drug Abuse (NIDA) | 2010-10-31 |
| A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia (NCT01214135) | AstraZeneca | 2010-10-01 |
| Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis (NCT01216891) | Research Foundation for Mental Hygiene, Inc. | 2010-10-01 |
| Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan (NCT01357005) | Far Eastern Memorial Hospital | 2010-10-01 |
| Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness (NCT01244854) | VA Office of Research and Development | 2010-10-01 |
| Adult Study Oxytocin - Behavioral (NCT02567032) | University of California, San Francisco | 2010-10-01 |
| Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia (NCT01420575) | VA Nebraska Western Iowa Health Care System | 2010-10-01 |
| Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan (NCT01249079) | China Medical University Hospital | 2010-10-01 |
| A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia (NCT01258920) | Janssen Pharmaceutical K.K. | 2010-10-01 |
| An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia (NCT01175135) | Pfizer | 2010-10-01 |
| A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia (NCT01212575) | AstraZeneca | 2010-10-01 |
| An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia (NCT01299389) | Janssen Pharmaceutical K.K. | 2010-10-01 |
| Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia (NCT01222793) | National Institute on Drug Abuse (NIDA) | 2010-09-26 |
| Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia (NCT01292577) | University of Pittsburgh | 2010-09-01 |
| Effectiveness of Ziprasidone for Patients With Schizophrenia (NCT01198353) | Soonchunhyang University Hospital | 2010-09-01 |
| PHARMO Institute Seroquel Safety Study (NCT01342120) | AstraZeneca | 2010-09-01 |
| DAAOI-1 Treatment for Treatment-resistant Schizophrenia (NCT01390376) | China Medical University Hospital | 2010-09-01 |
| Waist Circumference Measurements in Schizophrenic Patients (NCT01243034) | Changhua Christian Hospital | 2010-08-01 |
| Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia (NCT01160679) | AstraZeneca | 2010-08-01 |
| A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (NCT01942148) | Otsuka Pharmaceutical Co., Ltd. | 2010-08-01 |
| Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States (NCT03257592) | Johns Hopkins University | 2010-08-01 |
| Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning (NCT01161277) | Oslo University Hospital | 2010-08-01 |
| Adult Oxytocin Study (NCT02577575) | University of California, San Francisco | 2010-08-01 |
| Mindfulness-based Illness Management Program for Schizophrenia (NCT01667601) | The Hong Kong Polytechnic University | 2010-08-01 |
| Switching to Iloperidone From Other Antipsychotics in Schizophrenia (NCT01207414) | Novartis | 2010-08-01 |
| Yoga as Cognitive Remediation in Schizophrenia (NCT01879709) | Dr. Ram Manohar Lohia Hospital | 2010-08-01 |
| Randomized Double Blind Placebo Control Study in Patients with Schizophrenia (NCT01602029) | Pakistan Institute of Living and Learning | 2010-08-01 |
| Salsalate for Insulin Resistance in Schizophrenia (NCT01182727) | University of Maryland, Baltimore | 2010-08-01 |
| A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (NCT01942161) | Otsuka Pharmaceutical Co., Ltd. | 2010-08-01 |
| Reduction of Cardiovascular Risk in Severe Mental Illness (NCT01182012) | Consorci Hospitalari de Vic | 2010-08-01 |
| Benefits Management for People With Psychiatric Disabilities (NCT01329393) | Yale University | 2010-08-01 |
| Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital (NCT01193166) | Ortho-McNeil Janssen Scientific Affairs, LLC | 2010-08-01 |
| Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia (NCT01242371) | Sheppard Pratt Health System | 2010-08-01 |
| A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (NCT01143090) | Sumitomo Pharma America, Inc. | 2010-08-01 |
| Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations (NCT01181960) | Janssen Scientific Affairs, LLC | 2010-08-01 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1) (NCT01206517) | Organon and Co | 2010-07-18 |
| Antipsychotics and Gene Expression in Soft Tissues (NCT01185743) | Medical University of Vienna | 2010-07-01 |
| Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia (NCT01121042) | Bayside Health | 2010-07-01 |
| Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone (NCT01173874) | New York State Psychiatric Institute | 2010-07-01 |
| Acute Glycine Pharmacodynamic Study (NCT01610011) | Mclean Hospital | 2010-07-01 |
| An Integrated Program for the Treatment of First Episode of Psychosis (NCT01321177) | Northwell Health | 2010-07-01 |
| Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning (NCT01730781) | Yale University | 2010-07-01 |
| Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia (NCT01123317) | University of Maryland, Baltimore | 2010-07-01 |
| The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours (NCT01377896) | AstraZeneca | 2010-07-01 |
| An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia (NCT01129882) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2010-06-24 |
| The Effectiveness Of Auricular Acupressure On Body Weight Parameters On Patients With Schizophrenia (NCT01167348) | TsaoTun Psychiatric Center, Department of Health, Taiwan | 2010-06-01 |
| A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents (NCT01143077) | Sumitomo Pharma America, Inc. | 2010-06-01 |
| A Long-Term, Open-Label, Study on Schizophrenia (NCT01129674) | Eli Lilly and Company | 2010-06-01 |
| Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis (NCT01196286) | University of Arizona | 2010-06-01 |
| Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia (NCT01082588) | Massachusetts General Hospital | 2010-06-01 |
| How Reducing Anxiety in Schizophrenia (NCT02390271) | Institut de Recherche Biomedicale des Armees | 2010-06-01 |
| The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia (NCT01493622) | Central South University | 2010-06-01 |
| Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study (NCT01133080) | Shalvata Mental Health Center | 2010-06-01 |
| Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation (NCT00801567) | Mclean Hospital | 2010-06-01 |
| Effects of Ketamine and Risperidone on Cognition (NCT01140620) | University of Manchester | 2010-06-01 |
| Different Safety Profile of Risperidone and Paliperidone Extended-release (NCT01284959) | Chonbuk National University Hospital | 2010-06-01 |
| Long-term Study of Cariprazine in Patients With Schizophrenia (NCT01104792) | Forest Laboratories | 2010-05-31 |
| Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment (NCT06326840) | Taipei Medical University Hospital | 2010-05-31 |
| 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124) (NCT01098110) | Organon and Co | 2010-05-25 |
| Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125) (NCT01142596) | Organon and Co | 2010-05-25 |
| The Evaluation of Therapeutic Efficacy on the Integrated Group Psychotherapy for Patients With Schizophrenia (NCT01139099) | National Taiwan University Hospital | 2010-05-01 |
| 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated (NCT01157351) | Janssen Scientific Affairs, LLC | 2010-05-01 |